S-8 POS 1 ds8pos.htm POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 Post-Effective Amendment No. 1 to Form S-8

As filed with the Securities and Exchange Commission on November 6, 2009

Registration No. 333-92424

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

POST-EFFECTIVE AMENDMENT NO. 1 TO

Form S-8 Registration Statement No. 33-5111

Form S-8 Registration Statement No. 2-86618

Form S-8 Registration Statement No. 2-91724

Form S-8 Registration Statement No. 33-24013

Form S-8 Registration Statement No. 33-29791

Form S-8 Registration Statement No. 333-144678

Form S-8 Registration Statement No. 333-92424

Form S-8 Registration Statement No. 333-132932

Form S-8 Registration Statement No. 333-118254

Form S-8 Registration Statement No. 333-74585

Form S-8 Registration Statement No. 333-141304

UNDER

THE SECURITIES ACT OF 1933

 

 

AMGEN INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   95-3540776
(State of Incorporation)   (I.R.S. Employer Identification No.)

One Amgen Center Drive

Thousand Oaks, California 91320-1799

(805) 447-1000

(Address of principal executive offices, including zip code)

1984 Stock Option Plan

1981 Incentive Stock Option Plan

Nonqualified Stock Option Plan of Amgen Inc.

Amended and Restated 1988 Stock Option Plan of Amgen Inc.

Amended and Restated 1987 Directors’ Stock Option Plan

Amgen Inc. Assumed Ilypsa, Inc. Stock Plan (f/k/a the Ilypsa Inc. 2003 Stock Plan)

Immunex Corporation Stock Option Plan for Nonemployee Directors

Amgen Inc. Amended and Restated 1999 Employee Stock Purchase Plan (f/k/a the Immunex Corporation

1999 Employee Stock Purchase Plan)

Amgen Inc. Profit Sharing 401(k) Plan and Trust (f/k/a the Immunex Corporation Profit Sharing 401(k) Plan

and Trust)

Abgenix, Inc. 1998 Director Option Plan, as amended and restated

Tularik Inc. 1991 Stock Plan, as amended

Tularik Inc. Amended and Restated 1997 Non-Employee Directors’ Stock Option Plan, as amended

Amgen Salary Savings Plan (f/k/a Tularik Salary Savings Plan)

Perlman Nonstatutory Stock Option Agreement

Amgen Limited Sharesave Plan

Amgen Technology Ireland Irish Tax Approved Share Plan

(Full title of the plan)

 

 

David J. Scott, Esq.   Copy to:
Senior Vice President, General Counsel   Charles K. Ruck
and Secretary   Latham & Watkins LLP
One Amgen Center Drive   650 Town Center Drive, Suite 2000
Thousand Oaks, California 91320-1799   Costa Mesa, California 92626
(805) 447-1000   (714) 540-1235
(Name, address, including zip code, and telephone number, including area code, of agent for service)

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act (Check one):

 

Large Accelerated filer   x   Accelerated filer   ¨
Non-Accelerated filer   ¨   Smaller reporting company   ¨

(Do not check if a smaller reporting company)

 

 

 


EXPLANATORY NOTE / DEREGISTRATION OF UNSOLD SECURITIES

Amgen Inc. (the “Company”) previously registered shares of the Company’s common stock, $0.0001 par value per share, under the following registration statements (the “Registration Statements”) concerning shares issuable under certain employee benefit and equity plans and agreements. The Company is filing these post-effective amendments to the Registration Statements (“Post-Effective Amendments”) in order to deregister any securities registered and unsold under the Registration Statements and to terminate the Registration Statements. The approximate number of unsold shares is set forth below with respect to each Registration Statement. The shares are being removed from registration and the Registration Statements are being terminated because the plans referenced below have now expired or been terminated and all shares that were issuable under the plans have been issued.

 

Registration
No.

  

Date Filed
With the
SEC

  

Name of Equity Plan or Agreement

   Number of Shares
Originally
Registered1
   Approximate
Number of
Shares
Deregistered2

2-91724

33-5111

  

6/15/84

4/23/86

   1984 Stock Option Plan    3,000,000

7,200,000

   0

2,502,928

2-86618

   9/20/83    1981 Incentive Stock Option Plan and Nonqualified Stock Option Plan of Amgen Inc.    47,987,328    7,815,552

33-24013

   8/26/88    Amended and Restated 1988 Stock Option Plan of Amgen Inc.    36,000,000    249,224

33-29791

33-42501

  

7/6/89

8/28/91

   Amended and Restated 1987 Directors’ Stock Option Plan    4,800,000

2,400,000

   0

2,112,052

333-144678

   7/18/2007    Amgen Inc. Assumed Ilypsa, Inc. Stock Plan (f/k/a the Ilypsa Inc. 2003 Stock Plan)    21,992    3,494

333-92424

   7/16/2002    Immunex Corporation Stock Option Plan for Nonemployee Directors    347,880    15,600
      Amgen Inc. Amended and Restated 1999 Employee Stock Purchase Plan (f/k/a the Immunex Corporation 1999 Employee Stock Purchase Plan)    1,298,005    1,251,841
      Amgen Inc. Profit Sharing 401(k) Plan and Trust (f/k/a the Immunex Corporation Profit Sharing 401(k) Plan and Trust)    649,455    432,235

333-132932

   4/3/2006    Abgenix, Inc. 1998 Director Option Plan, as amended and restated    89,900    0

333-118254

   8/16/2004    Tularik Inc. 1991 Stock Plan, as amended    38,710    4,059
      Tularik Inc. Amended and Restated 1997 Non-Employee Directors’ Stock Option Plan, as amended    90,200    39,689
      Amgen Salary Savings Plan (f/k/a Tularik Salary Savings Plan)    28,664    28,304
      Perlman Nonstatutory Stock Option Agreement    9,020    0

333-74585

   3/17/1999    Amgen Limited Sharesave Plan    400,000    372,839

333-141304

   3/15/2007    Amgen Technology Ireland Irish Tax Approved Share Plan    600,000    592,168

 

1

The number of shares originally registered have been adjusted as appropriate to reflect the following stock splits effected by the Company: 2 for 1 stock split on August 10, 1990; 3 for 1 stock split on September 10, 1991; 2 for 1 stock split on August 15, 1995; 2 for 1 stock split on February 26, 1999; and 2 for 1 stock split on November 19, 1999.

 

2

A “0” in this column indicates that all shares originally registered under the registration statement were issued.


SIGNATURES

In accordance with the requirements of the Securities Act of 1933, as amended, the registrant, Amgen Inc., certifies that it has reasonable grounds to believe that it meets all of the requirements for filing these Post-Effective Amendments and has duly caused and authorized the officers whose signatures appear below to sign these Post-Effective Amendments on its behalf by the undersigned, in the City of Thousand Oaks, State of California, on November 6, 2009.

 

AMGEN INC.

By:  

/s/ David J. Scott

  David J. Scott
  Senior Vice President, General Counsel and Secretary


POWER OF ATTORNEY

Each person whose signature appears below hereby authorizes and appoints Kevin W. Sharer and Robert A. Bradway and David J. Scott as attorneys-in-fact and agents, each acting alone, with full powers of substitution to sign on his behalf, individually and in the capacities stated below, and to file any and all amendments (including these Post-Effective Amendments filed herewith) to the Registration Statements listed herein above, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting to those attorneys-in-fact and agents full power and authority to perform any other act on behalf of the undersigned required to be done.

Pursuant to the requirements of the Securities Act of 1933, these Post-Effective Amendments have been signed by the following persons in the capacities and on the dates indicated.

 

Signature

 

Title

 

Date

/s/    Kevin W. Sharer

  Chairman of the Board, Chief Executive Officer and President, and Director (Principal Executive Officer)   November 6, 2009

Kevin W. Sharer

   

/s/    Robert A. Bradway

  Executive Vice President and Chief Financial Officer (Principal Financial Officer)   November 6, 2009

Robert A. Bradway

   

/s/    Michael A. Kelly

  Vice President, Finance and Chief Accounting Officer (Principal Accounting Officer)   November 6, 2009

Michael A. Kelly

   

/s/    David Baltimore

  Director   November 6, 2009

David Baltimore

   

/s/    Frank J. Biondi, Jr.

  Director   November 6, 2009

Frank J. Biondi, Jr.

   

/s/    François de Carbonnel

  Director   November 6, 2009

François de Carbonnel

   

/s/    Jerry D. Choate

  Director   November 6, 2009

Jerry D. Choate

   

/s/    Vance D. Coffman

  Director   November 6, 2009

Vance D. Coffman

   

/s/    Frederick W. Gluck

  Director   November 6, 2009

Frederick W. Gluck

   


/s/    Rebecca M. Henderson

  Director   November 6, 2009

Rebecca M. Henderson

   

/s/    Frank C. Herringer

  Director   November 6, 2009

Frank C. Herringer

   

/s/    Gilbert S. Omenn

  Director   November 6, 2009

Gilbert S. Omenn

   

/s/    Judith C. Pelham

  Director   November 6, 2009

Judith C. Pelham

   

/s/    J. Paul Reason

  Director   November 6, 2009

J. Paul Reason

   

/s/    Leonard D. Schaeffer

  Director   November 6, 2009

Leonard D. Schaeffer

   


EXHIBIT INDEX

 

Exhibit
Number

 

Description

24.1   Power of Attorney (included on signature page)